Apitope International

Foundation date

2008

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Apitope focuses on immunotherapies for the treatment of autoimmune and allergic diseases, including multiple sclerosis, factor VIII intolerance, uveitis and Graves’ disease. Apitope has a discovery platform which enables the selection of highly specific disease-modifying peptide therapies. These therapies selectively reinstate immune tolerance to the disease target of interest. Apitope has generated a pipeline of 6 clinical and preclinical programmes. The lead programme is partnered with Merck Serono.

Upcoming events

Latest news

  • Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease

    1 day ago

  • Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study

    1 day ago

  • BISC Global opens in Switzerland

    Wednesday August 12th 2020